- Home
- OTLK vs ZDGE Comparison
OTLK vs ZDGE Comparison
Compare OTLK & ZDGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- ZDGE
- Stock Information
- Founded
- OTLK 2010
- ZDGE 2008
- Country
- OTLK United States
- ZDGE United States
- Employees
- OTLK N/A
- ZDGE N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- ZDGE Computer Software: Prepackaged Software
- Sector
- OTLK Health Care
- ZDGE Technology
- Exchange
- OTLK Nasdaq
- ZDGE Nasdaq
- Market Cap
- OTLK 42.8M
- ZDGE 42.3M
- IPO Year
- OTLK 2016
- ZDGE N/A
- Fundamental
- Price
- OTLK $1.21
- ZDGE $2.56
- Analyst Decision
- OTLK Buy
- ZDGE
- Analyst Count
- OTLK 5
- ZDGE 0
- Target Price
- OTLK $5.25
- ZDGE N/A
- AVG Volume (30 Days)
- OTLK 1.4M
- ZDGE 97.0K
- Earning Date
- OTLK 08-14-2025
- ZDGE 12-15-2025
- Dividend Yield
- OTLK N/A
- ZDGE 2.54%
- EPS Growth
- OTLK N/A
- ZDGE N/A
- EPS
- OTLK N/A
- ZDGE N/A
- Revenue
- OTLK $1,505,322.00
- ZDGE $29,398,000.00
- Revenue This Year
- OTLK N/A
- ZDGE $2.37
- Revenue Next Year
- OTLK $342.80
- ZDGE $4.54
- P/E Ratio
- OTLK N/A
- ZDGE N/A
- Revenue Growth
- OTLK N/A
- ZDGE N/A
- 52 Week Low
- OTLK $0.79
- ZDGE $1.73
- 52 Week High
- OTLK $6.98
- ZDGE $4.89
- Technical
- Relative Strength Index (RSI)
- OTLK 45.22
- ZDGE 37.20
- Support Level
- OTLK $1.28
- ZDGE $2.21
- Resistance Level
- OTLK $1.31
- ZDGE $3.85
- Average True Range (ATR)
- OTLK 0.09
- ZDGE 0.28
- MACD
- OTLK -0.01
- ZDGE -0.10
- Stochastic Oscillator
- OTLK 0.00
- ZDGE 21.52
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.